section name header

Indications

BEERS REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: edema, HF, hypertension, MI.

Derm: rash.

EENT: blurred vision, tinnitus.

Endo: IV: hypoglycemia.

F and E: hyperkalemia.
IV: dilutional hyponatremia.

GI: constipation, dyspepsia, nausea, vomiting, discomfort.
PO: GI BLEEDING, HEPATOTOXICITY, necrotizing enterocolitis, PANCREATITIS.

GU: cystitis, hematuria, renal failure.

Hemat: blood dyscrasias, prolonged bleeding time, thrombocytopenia.

Local: phlebitis at IV site.

Neuro: dizziness, drowsiness, headache, psychic disturbances, STROKE.

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS).

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

see Calculator

Anti-inflammatory

PDA Closure

US Brand Names

Indocin, Tivorbex

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antirheumatics, ductus arteriosus patency adjuncts (IV only), nonopioid analgesics

Pharmacologic Classification:

Pharmacokinetics

Absorption: Well absorbed after oral administration in adults, incomplete oral absorption in neonates.

Distribution: Crosses the blood-brain barrier.

Protein Binding: 99%.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-life: Neonates <2 wk: 20 hr; Neonates >2 wk: 11 hr; Adults: 2.6–11 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
PO (analgesic)30 min0.5–2 hr4–6 hr
PO-ER (analgesic)30 minunknown4–6 hr
PO (anti-inflammatory)up to 7 days1–2 wk4–6 hr
PO-ER (anti-inflammatory)up to 7 days1–2 wk4–6 hr
IV (closure of PDA)up to 48 hrunknownunknown

Patient/Family Teaching

Pronunciation

in-doe-METH-a-sin

Code

NDC Code*